Kornimate/medical-research-clean huggingface dataset:
quantify the degree of pain relief of pelvic congestion syndrome following gonadal vein embolization

Conditions: Pelvic Congestive Syndrome; Pelvic Pain

Summary: the primary objective is to quantify the degree of pain relief in patients undergoing gonadal vein embolization with coils as well as identify clinical or imaging factors that are predictive of a positive response to treatment, or poor response to treatment.

chronic pelvic pain affects almost 40% of women during their lifetime. pelvic congestion syndrome (pcs) accounts for up to 30% of those with chronic pelvic pain. the most common underlying cause of pcs is incompetence or obstruction of the gonadal veins, resulting in painful congestion of the pelvic and perineal venous vasculature. medical treatment is first line, and aims to suppress ovarian function and induce vasoconstriction of the venous system. unfortunately, efficacy and long-term pain relief from medical therapy is limited. coil embolization of the gonadal veins has been shown to decrease pain in those affected by pcs, although the degree of relief has not yet been quantified.

Eligibility criteria:
inclusion criteria: * female patients 18 years of age or older * meet the clinical and imaging criteria for the diagnosis of pcs and have no contraindications to coil embolization of the gonadal veins. * patients who are treated with coil embolization of the gonadal veins in the interventional radiology division between october 1, 2018 to october 1, 2019. exclusion criteria: * patients less than 18 years of age. * patients who are found to have an underlying cause of pelvic congestion syndrome unrelated to venous congestion and insufficiency. this includes, but is not limited to, nutcracker syndrome, or a mass resulting in extrinsic compression of the gonadal veins. * patients who have received prior surgical therapy for pcs, including bilateral salpingo-oophorectomy (tah-bso), gonadal vein resection, or gonadal vein ligation.

Keywords: gonadal vein embolization
creation of a biospecimen repository from patients with interstitial lung diseases (ild)

Conditions: Interstitial Lung Disease

Summary: to develop a repository of blood samples from patients with ild to support future studies into the development of such biomarkers. patients with pneumonia and healthy patients will also be recruited as a control group.

the proposed biospecimen repository would be derived from patients diagnosed with ild. this is to include 500 patients in the repository, with each patient contributing one blood sample. patients with pneumonia and healthy patients will also be recruited as a control group.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of ild or any fibrotic disease of the lung or a diagnosis of pneumonia * patients willing to provide written informed consent exclusion criteria: * unwillingness/unable to give blood samples

Keywords: ild
icibs trial - improving patient information about bowel cancer screening - a decision aid trial

Conditions: Colorectal Cancer Screening

Summary: this project has been completed and consisted of a randomised trial of six tailored decision aids giving patients evidence-based information about faecal occult blood test screening for bowel cancer. 314 australians aged between 50-74 years were recruited from five general practices and randomised to received either the tailored decision aid with age-gender and family history specific information and values clarification exercise or a standard government information sheet. the decision aid significantly increased the proportion of people who were informed participants in the screening program.


Eligibility criteria:
inclusion criteria: * people aged 50-74 years who were eligible for fobt screening under current australian guidelines and had not had screening for colorectal cancer in the preceding two years exclusion criteria: * poor english, impaired cognition, significant comorbidity

Keywords: decision aid faecal occult blood test colorectal cancer screening informed decision-making
serum cholinesterase level in aluminum phosphide poisoning, the possible proposing role of atropin & pralidoxime

Conditions: Toxicity;Chemical

Summary: metal phosphides are widely used as a rodenticide and insecticide and poisoning with these substances has a very high mortality. the aim of this study was to evaluate the butyrylcholinesterase (buch) level in poisoning with metal phosphides.

today, the use of pesticides in the world is considered as a recognized health it is estimated that around 30% of global suicides are due to pesticide self-poisoning . metal phosphides pesticides are highly toxic, low cost, and are easily accessible as rodenticide agents and used for self-poisoning . aluminum phosphide (alp) are among the most important metal phosphides. poisoning with these agents is frequently seen in india, srilanka and iran. in a recent study, the incidence of fatal aluminum phosphide poisoning cases referred for phosphine analysis was 5.22 and 37.02 per million of population of tehran, iran in 2006 and 2013, respectively (9).the mechanism of toxicity is not clearly defined. alp toxicity is related to the production of phosphine gas. phosphine inhibits cytochrome c oxidase and causes mitochondrial destruction and inhibits oxidative respiration which leads to anaerobic metabolism, severe metabolic acidosis, multi-organ dysfunction and death. phosphine can lead to severe cardiac suppression and cardiogenic shock. one of the proposed mechanisms of toxicity is the reduction of the true cholinesterase and serum cholinesterase (butyrylcholinesterase) enzyme, but usually do not show obvious clinical manifestations .

Eligibility criteria:
inclusion criteria: cases of aluminum phosphide poisoning - exclusion criteria: concomitant ingestion -

Keywords: serum cholinestrase, atropin, aluminum phosphide
andrographis paniculata vs boesenbergia rotunda vs control in asymptomatic covid-19

Conditions: Covid19

Summary: the purpose of this study is to examine the effect of andrographis extract, boesenbergia extract compared to standard treatment in asymptomatic covid patients.


Eligibility criteria:
inclusion criteria: 1. age 18- 60 years old 2. have been diagnosed as new covid-19 case by rt-pcr since disease onset to admission less than 7 days 3. have asymptomatic infection assessed by the world health organization (who) disease category 4. do not have any of following disease or conditions 1. body weight \> 90 kg or bmi \> 30 kg/m2 2. hypertension that needs antihypertensive medication 3. diabetes 4. cardiovascular diseases including congenital heart disease 5. cerebrovascular diseases 6. chronic kidney and chronic liver diseases 7. copd or chronic lung diseases 8. lymphocyte \<1,000 cells/mm3 9. late-stage cancer 10. auto-immune disease (e.g., sle, rheumatoid arthritis, multiple sclerosis, etc.) or currently on immunosuppressive drug 11. coagulation disorders or platelet disorders and are being treated with anticoagulants such as warfarin, clopidogrel 12. pregnancy 5. willing to participate with the study and sign inform consents. (withdrawal criteria) 1. patients withdraw from the study 2. have severe adverse effect that may relate to andographolide or boesenbergia

Keywords: treatment andrographis boesenbergia covid19
mhealth for phosphorus management in ckd.

Conditions: Dialysis Related Complication

Summary: the project aims to generate an mhealth environment in which ckd patients are empowered in terms of the self-management of their hyperphosphatemia pathology, while under medical supervision. such environment will allow nephrologists to inform patients beyond their traditional point-of-care and will allow patients to provide feedback on their condition in a timely manner that benefits the ckd collective. in this way we delve in a technological area that has been argued that remains underutilized within nephrology (1) and that should be perceived as an opportunity for ckd (2). in our work, we will build from recent related efforts in the control of hyperphosphatemia (3).

the working hypotheses are listed as follows: 1. hyperphosphatemia is an important problem in the ckd realm, but difficult to manage because patients are often not aware of its importance. in addition, current clinical practice does not allow nephrologists to evaluate the patient's real understanding of their recommendations. 2. the patient could benefit from a smartphone-based interactive virtual assistant tool: an integrated personalized management system to achieve a form of participatory, personalized, predictive and preventive medicine in the specific domain of a pathology associated to ckd. 3. the combination of a flexible information channel with an interactive data visualization tool on mobile devices can be a most intuitive way to communicate with the patient, particularly if it allows comparison with other patients in similar situation. additionally, data visualization can assist nephrologists in the clinical management of patients. primary objective: 1-analysis of the superiority of a medical mobile application for patient support to educate ckd patients on how to self-manage their phosphate levels versus standard of care in lowering serum phosphorus by assessing changes in serum phosphorus comparing baseline with 6-months follow-up. secondary objectives: 1. adherence to treatment with phosphate binders. 2. impact in quality of life of patients with ckd. 3. satisfaction of such a tool.

Eligibility criteria:
inclusion criteria: 1- eligible patients will be stage 4-5 ckd patients, including end-stage renal disease (esrd) on dialysis, aged \>18 with hyperphosphatemia (serum phosphorus concentration \>1.94 mmol/l) and stable dose of phosphate binders for \>1 month before screening. exclusion criteria: 1. patients with intact parathyroid hormone concentration \>800 ng/l (88 pmol/l) or if parathyroidectomy will be planned or expected. 2. patients with significant gastro-intestinal (gi) or hepatic disorders. 3. patients with major gi surgery.

Keywords: mhealth hyperphosphatemia
visfatin levels before and after periodontal treatment

Conditions: Periodontal Diseases

Summary: the purpose of this study was to evaluate visfatin levels in different stages of periodontal diseases and health, moreover the effect of non-surgical periodontal therapy on visfatin levels in gingival crevicular fluid (gcf) and serum.

total of 45 patients were divided into three groups based on their clinical and radiographical examination. group 1 chronic periodontitis (n: 15), group 2 plaque induced gingivitis (n: 15) and group 3 periodontal health (n: 15). gcf and serum samples were collected before treatment and 1, 3, 6 months after treatment and were assayed using enzyme linked immunosorbent assay kit.

Eligibility criteria:
group 1 inclusion criteria: * gi\>1, ppd≥5mm, cal≥5mm with alveolar bone loss radiographically. * systematically healthy patients group 2 inclusion criteria: * no alveolar bone and attachment loss * inflammation signs such as redness, edema and increased bop levels, * gi≥2, ppd≤3mm, cal≤3mm. * systematically healthy patients group 3 inclusion criteria: * no bone and attachment loss, * gi=0, ppd≤3mm, cal≤3mm * systematically healthy patients exclusion criteria for all groups: * aggressive periodontitis, * oral pathologies, * patients with any other systemic diseases, * pregnant women and those in the lactation period, * patients with smoking habit and taking medication * patients received periodontal therapy in last 6 months

Keywords: visfatin gcf serum non-surgical periodontal treatment.
study to evaluate the pharmacokinetics (pk), pharmacodynamics (pd), and usability of abaloparatide-solid microstructured transdermal system (smts) in postmenopausal women with low bone mineral density (bmd)

Conditions: Postmenopausal Osteoporosis

Summary: this was an open-label, single-center study to evaluate the usability of abaloparatide-smts by participants with low bmd.

this study aimed to evaluate the ability of participants to self-administer 300 μg abaloparatide-smts over a period of 29 days based on pk and pd markers.

Eligibility criteria:
inclusion criteria: * postmenopausal for at least 2 years * bmd t-score based on the female reference range \ -5.0 at the lumbar spine (l1-l4) or hip (femoral neck or total hip) by dual energy x-ray absorptiometry (dxa) * good general health as determined by medical history and physical exam (including vital signs, and has a body mass index up to 33 kilograms/square meter (kg/m\^2) * laboratory tests within the normal range including serum calcium (albumin-corrected), intact parathyroid hormone (pth), serum phosphorus, alkaline phosphatase, and thyroid stimulating hormone * serum 25-hydroxyvitamin d values ≥ 20 nanograms per milliliter (ng/ml) exclusion criteria: * history of prior external beam or implant radiation therapy involving the skeleton, other than radioiodine * history of bone disorders other than postmenopausal osteoporosis (such as paget's disease) * history of cancer within the last 5 years (with the exception of basal cell or squamous cancer of the skin) * history of cushing's disease, hypo or hyperparathyroidism, or malabsorptive syndromes within the past year * prior treatment with pth, pth-related peptide-derived drugs, or bone anabolic steroids, including abaloparatide, teriparatide, or pth (1-84) * prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past year (12 months). participants who have received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment * prior treatment with an investigational drug or device within the past 3 months or 5 half-lives of the investigational drug, whichever is longer

Keywords: postmenopausal osteoporosis transdermal delivery microstructure patch abaloparatide
cross fiber fascial manipulation and stretching techniques in overhead throwing athletes

Conditions: Overhead Throwing Athletes; Tennis Players, Bowlers, Volleyball Players

Summary: athletic training and sports participation is to enhance athletic performance. performance is however multifactorial i.e., depending upon several parameters including warm-up practice, training regimes and other interventions. stretching techniques that focus on increasing posterior shoulder soft tissue flexibility are commonly incorporated into prevention and treatment programs for the overhead athletes. gird is usually managed by stretching and soft tissue release of posterior shoulder capsule. fascial manipulation is a manual therapy technique used in the management of musculoskeletal disorders. this study aims to evaluate the comparative effects of cross fiber fascial manipulation with stretching techniques in overhead throwing athletes

this was a randomized clinical trial that was conducted at pakistan sports board and coaching center, lahore. non probability convenient sampling technique was used to collect the data as per inclusion criteria. 40 participants of this study were randomly allocated into 2 groups. 20 participants in each group. the group a received three sessions of fascial manipulation for two weeks. group b received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performed shoulder ir and cross-body adduction stretch in sitting position. three sets of the each stretch positions were held for 30 seconds with a 1 minute break between sets. a universal goniometer was used to measure internal rotation, external rotation, horizontal abduction, rowe score to assess function, pain, stability and motion, numeric pain rating scale (nprs) was used to assess pain. the data was analyzed via spss version 22.

Eligibility criteria:
inclusion criteria: * active male and female athletes were included. * age group was (18-40) . * overhead throwing athletes(tennis, volleyball, bowlers) were included in this study) * screening tests were taken to identify subjects with gird. gird was defined as more than 20o decrease in ir at 90o abduction in the dominant side compared to non-dominant side . * subjects who rated shoulder pain 5 or more in nprs/symptomatic with gird were recruited exclusion criteria : * any deformity * any radiculopathy * shoulder traumatic injuries( dislocation, subluxation, fracture) * systemic illness * subacromial impingement signs
feasibility and efficacy of cognitive-behavioral therapy for patients with adhd/behavioral addiction comorbidity

Conditions: ADHD; Behavioral Addiction

Summary: the main objective of this pilot study is to assess preliminary data on the feasibility of cbt and its evaluation in a randomised trial in patients with co-occurring adhd and behavioural addiction: evaluation and comparison of the 12-week retention rate of patients randomised to cbt compared with patients in the 'treatment as usual' control arm. in order to meet the objective, the patient will take part in a standardized assessment, followed by a therapeutic intervention and a new standardized assessment after the intervention. the standardized assessment consists as follows : * firstly, 7 self-questionnaires to be completed by the patient, lasting around 45 min, aimed at assessing his or her socio-demographic data; current symptoms, quality of life and functional impact related to adhd; impulsivity, emotion regulation and assessment of possible anxiety-depressive disorders. * then the patient will follow the 10 session of cognitivo behavioural psychotherapy. * at 12-weeks post-inclusion, an assessment visit is carried out during which a battery of tests will be administered. this is followed by a research interview with a professional, aimed at gathering his or her experiences.


Eligibility criteria:
inclusion criteria: * patient over 18 (age ≥ 18 years) * patient treated in an outpatient addictology department at the chu of brest, nantes or tours and presenting an adhd/behavioral addiction comorbidity * patient affiliated to a social security scheme * for patients treated with methylphenidate: no change in treatment dosage during the previous three months. * for patients not treated with methylphenidate: no introduction of methylphenidate within the next three months. exclusion criteria: * patients with psychotic disorders (assessed by clinician) * pregnant or breast-feeding women * patients under protective supervision (guardianship or curatorship) * persons under court protection * persons deprived of their liberty * patients who do not meet the eligibility criteria for cbt (e.g., cognitive impairment, hearing impairment). * physical inability to participate in cbt sessions (e.g., lack of telephone, foreseeable unavailability). * difficulty understanding self-questionnaires, including illiteracy. * participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome.

Keywords: cbt cognitive behavioral therapy
efficacy, safety, pharmacokinetics, and pharmacodynamics study of tolvaptan in pediatric congestive heart failure (chf) patients with volume overload

Conditions: Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Summary: to determine the efficacy, safety, and dose and regimen of tolvaptan in pediatric chf patients with volume overload


Eligibility criteria:
inclusion criteria: * patients with volume overload despite having received any of the following diuretic therapies in whom sufficient effects cannot be expected even if the dose of the diuretics is increased or in whom the investigator or subinvestigator judges that increasing the dose of the diuretics is difficult due to concerns regarding electrolyte abnormalities or other side effects * furosemide (oral administration) ≥0.5 mg/kg/day. azosemide 30 mg and torasemide 4 mg will be calculated as equivalent to furosemide 20 mg. * hydrochlorothiazide ≥2 mg/kg/day * trichlormethiazide ≥0.05 mg/kg/day * spironolactone ≥ 1 mg/kg/day * patients capable of complaining of thirst. patients unable to complain of thirst due to their young age can also be enrolled in the trial if strict management of fluid intake and excretion is conducted. however, even if such fluid management is possible, the patients in whom the investigator or subinvestigator judges that tolvaptan cannot be safely administered are to be excluded * patients who can be hospitalized from at least 3 days before start of tolvaptan administration until 2 days after the final administration. others exclusion criteria: * patients whose volume overload status shows improvement during the screening period or pretreatment observation period * patients who are unable to drink fluid (including patients who are unable to sense thirst) * patients whose circulatory blood flow is suspected to be decreased * patients with an assisted circulation apparatus * patients with hypernatremia (serum or blood sodium concentration exceeding 145 meq/l) others
evaluation of pediatric balance scale and quantitative balance parameters in patients with cerebral palsy

Conditions: Cerebral Palsy, Spastic; Balance; Distorted

Summary: this study aims to evaluate pediatric balance scale and quantitative balance and gait parameters assessed by balance master force plate in cerebral palsy (cp) patients who are ambulatory without an assistive device in daily life.

cp refers to a group of motion and posture disorders that limit activity and participation which is attributed to non-progressive disturbances in the developing fetus or infant brain. in cp, motor and sensory disorders are often accompanied by poor balance control. impaired balance control leads to increased risk of falling, which is a major kinesiologic problem in children who are ambulatory without an assistive device. functional balance in children is defined as the ability to maintain the center of gravity according to the base of support during typical childhood activities of daily living, school and play. the pediatric balance scale, a modification of the berg balance scale, was developed as a functional balance measure for children, easily administered without specialized equipment in a relatively short time. balance master® (neurocom international clackmas, oregon, usa) is a device consisting of a system that processes signals from an 18x60 inch plaque that transmits the vertical forces exerted through patient's feet to measure center of gravity position and postural control through a software program. the aim of this study is to compare pbs results with quantitative balance and gait parameters obtained from balance master in spastic cp patients who are independently ambulatory. the level of correlation between these measurement methods will be examined and superiority to each other in assessing balance problems in this patient group will be evaluated.

Eligibility criteria:
inclusion criteria: * patients diagnosed with spastic cerebral palsy * age between 4-18 years * sufficient cooperation to understand instructions and participate evaluations * gross motor function classification system (gmfcs) level i-ii * giving an informed consent exclusion criteria: * visual and vestibular deficits * botulinum-toxin a treatment within 3 months or having undergone an orthopaedic surgery 1 year prior to inclusion in the study * severe scoliosis (cobb angle \>40°) * uncontrolled seizures (seizure in previous 6 months) * having intrathecal baclofen pump * having undergone selective dorsal rhizotomy

Keywords: cerebral palsy balance